Delving into the Latest Updates on CellMed AG with Synapse

概览

关联

4

项与 CellMed AG 相关的临床试验

NCT01196728 / Completed临床1期

Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes

The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM.

开始日期2010-09-01

申办/合作机构

CellMed AG

NCT01165502 / Completed临床1期

Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

The primary objective is to assess the safety and tolerability of the GLP-1 peptide analogue CM3.1-AC100 after repeated subcutaneous (sc) doses.

开始日期2010-07-01

申办/合作机构

CellMed AG

NCT01028521 / Completed临床1期

Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

A first time in man, phase I study to assess the safety, tolerability and pharmacokinetics of single ascending doses of CM3.1-AC100 in healthy male volunteers.

开始日期2010-02-01

申办/合作机构

CellMed AG

100 项与 CellMed AG 相关的临床结果

登录后查看更多信息

0 项与 CellMed AG 相关的专利（医药）

登录后查看更多信息

100 项与 CellMed AG 相关的药物交易

登录后查看更多信息

100 项与 CellMed AG 相关的转化医学

登录后查看更多信息